News

The ALS Society of Canada (ALS Canada) today marks Rare Disease Day 2022 by calling on the Ontario government to champion the urgent need for faster access to approved therapies for people living with Amyotrophic Lateral Sclerosis (ALS) – a…

Toronto – With promising new therapies for amyotrophic lateral sclerosis (ALS) on the horizon, now is the time for ongoing investment in research discovery that will continue to fuel the development of treatments. That is why, together with Brain Canada, the…

The Canadian Agency for Drugs and Technology in Health (CADTH) today posted a call for patient input on oral edaravone. This is a key milestone and a hopeful indicator for the Canadian ALS community. ALS Canada will be preparing a…

As identified by the ALS Canada Research Team, here are the most newsworthy research stories of 2021 and a look ahead to 2022 with hope for what is to come.   A possible third treatment for ALS under review by…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada’s advocacy efforts as well as relevant developments within government. Please note that because ALS Canada advocates federally and provincially within Ontario,…

The province of Prince Edward Island (PEI) has listed Radicava (edaravone) on the public formulary under Special Authorization as a treatment for ALS. With this announcement, all provinces and territories across Canada – as well as Veterans Affairs Canada and…

Toronto, ON – The in-home support that the ALS Society of Canada provides to people living with ALS is highly valued by the community it serves and is something it had to evolve after the pandemic made physical distancing a public…

Update: July 7, 2022: Following Health Canada’s approval of ALBRIOZA (AMX0035) under a Notice of Compliance with Conditions (NOC/c), CADTH posted reimbursement recommendations for ALBRIOZA (AMX0035) in late June. ALS Canada provided feedback on the recommendations, bringing forward the perspectives…